Induction of NAD(P)H-quinone oxidoreductase 1 by antioxidants in female ACI rats is associated with decrease in oxidative DNA damage and inhibition of estrogen-induced breast cancer

Carcinogenesis

Volumn 33, Issue 1, 2012, Pages 156-163

  Singh, Bhupendra ^a   Bhat, Nimee K ^a   Bhat, Hari K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ASCORBIC ACID; BUTYLATED HYDROXYANISOLE; ESTRADIOL; NAD(P)H QUINONE OXIDOREDUCTASE 1; OXIDOREDUCTASE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION;

EID: 84855375797     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr237     Document Type: Article

References (55)

1. Bhat,H.K. et al. (2003) Critical role of oxidative stress in estrogen-induced carcinogenesis. Proc. Natl. Acad. Sci. USA, 100, 3913-3918.
2. Cavalieri,E.L. et al. (1997) Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc. Natl. Acad. Sci. USA, 94, 10937-10942.
3. Henderson,B.E. et al. (2000) Hormonal carcinogenesis. Carcinogenesis, 21, 427-433.
4. Mense,S.M. et al. (2008) Estrogen-induced breast cancer: alterations in breast morphology and oxidative stress as a function of estrogen exposure. Toxicol. Appl. Pharmacol., 232, 78-85.
5. Mense,S.M. et al. (2009) Vitamin C and alpha-naphthoflavone prevent estrogen-induced mammary tumors and decrease oxidative stress in female ACI rats. Carcinogenesis, 30, 1202-1208.
6. Singh,B. et al. (2009) Antioxidant butylated hydroxyanisole inhibits estrogen-induced breast carcinogenesis in female ACI rats. J. Biochem. Mol. Toxicol., 23, 202-211.
7. Gaikwad,N.W. et al. (2008) The molecular etiology of breast cancer: evidence from biomarkers of risk. Int. J. Cancer, 122, 1949-1957.
8. Gaikwad,N.W. et al. (2009) Urine biomarkers of risk in the molecular etiology of breast cancer. Breast Cancer (Auckl), 3, 1-8.
9. Cavalieri,E.L. et al. (2010) Depurinating estrogen-DNA adducts in the etiology and prevention of breast and other human cancers. Future Oncol., 6, 75-91.
10. Clemons,M. et al. (2001) Estrogen and the risk of breast cancer. N. Engl. J. Med., 344, 276-285.
11. Jefcoate,C.R. et al. (2000) Tissue-specific synthesis and oxidative metabolism of estrogens. J. Natl. Cancer Inst. Monogr., 27, 95-112.
12. Liehr,J.G. et al. (1993) 32P-postlabelling in studies of hormonal carcinogenesis. IARC Sci. Publ., 124, 149-155.
13. Liehr,J.G. et al. (1990) Free radical generation by redox cycling of estrogens. Free Radic. Biol. Med., 8, 415-423.
14. Yager,J.D. et al. (2006) Estrogen carcinogenesis in breast cancer. N. Engl. J. Med., 354, 270-282.
15. Zahid,M. et al. (2006) The greater reactivity of estradiol-3,4-quinone vs estradiol-2,3-quinone with DNA in the formation of depurinating adducts: implications for tumor-initiating activity. Chem. Res. Toxicol., 19, 164-172.
16. Li,J.J. et al. (1987) Estrogen carcinogenesis in Syrian hamster tissues: role of metabolism. Fed. Proc., 46, 1858-1863.
17. Newbold,R.R. et al. (2000) Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens. Cancer Res., 60, 235-237.
18. Patel,M.M. et al. (2004) Differential oxidant potential of carcinogenic and weakly carcinogenic estrogens: involvement of metabolic activation and cytochrome P450. J. Biochem. Mol. Toxicol., 18, 37-42.
19. Liehr,J.G. et al. (1986) Carcinogenicity of catechol estrogens in Syrian hamsters. J. Steroid Biochem., 24, 353-356.
20. Yager,J.D. (2000) Endogenous estrogens as carcinogens through metabolic activation. J. Natl Cancer Inst. Monogr., 27, 67-73.
21. Kwak,M.K. et al. (2004) Chemoprevention by 1,2-dithiole-3-thiones through induction of NQO1 and other phase 2 enzymes. Methods Enzymol., 382, 414-423.
22. Shen,J. et al. (2010) Inactivation of the quinone oxidoreductases NQO1 and NQO2 strongly elevates the incidence and multiplicity of chemically induced skin tumors. Cancer Res., 70, 1006-1014.
23. Gaikwad,N.W. et al. (2007) Evidence from ESI-MS for NQO1-catalyzed reduction of estrogen ortho-quinones. Free Radic. Biol. Med., 43, 1289-1298.
24. Lu,F. et al. (2008) Resveratrol prevents estrogen-DNA adduct formation and neoplastic transformation in MCF-10F cells. Cancer Prev. Res. (Phila. Pa), 1, 135-145.
25. Ross,D. et al. (2000) NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem. Biol. Interact., 129, 77-97.
26. Zahid,M. et al. (2008) Prevention of estrogen-DNA adduct formation in MCF-10F cells by resveratrol. Free Radic. Biol. Med., 45, 136-145.
27. Dhakshinamoorthy,S. et al. (2000) Small maf (MafG and MafK) proteins negatively regulate antioxidant response element-mediated expression and antioxidant induction of the NAD(P)H: quinone oxidoreductase1 gene. J. Biol. Chem., 275, 40134-40141.
28. Kwak,M.K. et al. (2003) Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J. Biol. Chem., 278, 8135-8145.
29. Reddy,N.M. et al. (2007) Genetic dissection of the Nrf2-dependent redox signaling-regulated transcriptional programs of cell proliferation and cytoprotection. Physiol. Genomics, 32, 74-81.
30. Kensler,T.W. et al. (2010) Nrf2: friend or foe for chemoprevention? Carcinogenesis, 31, 90-99.
31. Kensler,T.W. et al. (2007) Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol., 47, 89-116.
32. Kaspar,J.W. et al. (2010) Antioxidant-induced phosphorylation of tyrosine 486 leads to rapid nuclear export of Bach1 that allows Nrf2 to bind to the antioxidant response element and activate defensive gene expression. J. Biol. Chem., 285, 153-162.
33. Akindahunsi,A.A. et al. (2005) Antioxidant indices of some green leafy vegetables. Trop. Sci., 45, 33-35.
34. Duffy,S.J. et al. (1999) Treatment of hypertension with ascorbic acid. Lancet, 354, 2048-2049.
35. Engelhart,M.J. et al. (2002) Dietary intake of antioxidants and risk of Alzheimer disease. JAMA, 287, 3223-3229.
36. Khaw,K.T. et al. (2001) Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: a prospective population study. European Prospective Investigation into Cancer and Nutrition. Lancet, 357, 657-663.
37. Kurl,S. et al. (2002) Plasma vitamin C modifies the association between hypertension and risk of stroke. Stroke, 33, 1568-1573.
38. Lee,S.H. et al. (2001) Vitamin C-induced decomposition of lipid hydroperoxides to endogenous genotoxins. Science, 292, 2083-2086.
39. Podmore,I.D. et al. (1998) Vitamin C exhibits pro-oxidant properties. Nature, 392, 559.
40. McCormick,D.L. et al. (1984) Inhibition of 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinogenesis by concomitant or postcarcinogen antioxidant exposure. Cancer Res., 44, 2858-2863.
41. Cha,Y.N. et al. (1982) Comparative effects of dietary administration of 2(3)-tert-butyl-4-hydroxyanisole and 3,5-di-tert-butyl-4-hydroxytoluene on several hepatic enzyme activities in mice and rats. Cancer Res., 42, 2609-2615.
42. Iverson,F. (1999) In vivo studies on butylated hydroxyanisole. Food Chem. Toxicol., 37, 993-997.
43. Han,X. et al. (1994) DNA single-strand breaks in kidneys of Syrian hamsters treated with steroidal estrogens: hormone-induced free radical damage preceding renal malignancy. Carcinogenesis, 15, 997-1000.
44. Bhat,H.K. et al. (2004) Suppression of calbindin D28K in estrogen-induced hamster renal tumors. J. Steroid Biochem. Mol. Biol., 92, 391-398.
45. Mense,S.M. et al. (2008) Preferential induction of cytochrome P450 1A1 over cytochrome P450 1B1 in human breast epithelial cells following exposure to quercetin. J. Steroid Biochem. Mol. Biol., 110, 157-162.
46. Benson,A.M. et al. (1980) Increase of NAD(P)H:quinone reductase by dietary antioxidants: possible role in protection against carcinogenesis and toxicity. Proc. Natl Acad. Sci. USA, 77, 5216-5220.
47. Ryan,N.M. (1996) Subcellular fractionation of animal tissues. Methods Mol. Biol., 59, 49-56.
48. Huang,X. et al. (2001) Importance of complete DNA digestion in minimizing variability of 8-oxo-dG analyses. Free Radic. Biol. Med., 31, 1341-1351.
49. Montano,M.M. et al. (2007) Protective roles of quinone reductase and tamoxifen against estrogen-induced mammary tumorigenesis. Oncogene, 26, 3587-3590.
50. Patrick,B.A. et al. (2011) Disruption of NAD(P)H:quinone oxidoreductase 1 gene in mice leads to 20S proteasomal degradation of p63 resulting in thinning of epithelium and chemical-induced skin cancer. Oncogene, 30, 1098-1107.
51. Harvell,D.M. et al. (2000) Rat strain-specific actions of 17beta-estradiol in the mammary gland: correlation between estrogen-induced lobuloalveolar hyperplasia and susceptibility to estrogen-induced mammary cancers. Proc. Natl Acad. Sci. USA, 97, 2779-2784.
52. Li,J.J. et al. (2002) Ploidy differences between hormone- and chemical carcinogen-induced rat mammary neoplasms: comparison to invasive human ductal breast cancer. Mol. Carcinog., 33, 56-65.
53. Bianco,N.R. et al. (2003) Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage. Mol. Endocrinol., 17, 1344-1355.
54. Mesia-Vela,S. et al. (2004) Dietary clofibrate inhibits induction of hepatic antioxidant enzymes by chronic estradiol in female ACI rats. Toxicology, 200, 103-111.
55. Peter Guengerich,F. et al. (2003) Cytochrome P450 1B1: a target for inhibition in anticarcinogenesis strategies. Mutat. Res., 523-524, 173-182.